Personalized Medicine in Rheumatology
The multibiomarker disease activity (MBDA) scale appears to be a very versatile tool, based on results presented at the 2015 annual meeting of the American College of Rheumatology.
Clinicians may be able to use the multibiomarker disease activity (MBDA) score to predict rheumatoid arthritis (RA) flares within a year of discontinuation of tumor necrosis factor inhibitor (TNFi).
The versatile multibiomarker disease activity (MBDA) score may be able to predict rheumatoid arthritis (RA) relapse within the first year of tapering disease-modifying antirheumatic drug (DMARD) treatment.
Autoantibodies are a key feature of rheumatoid arthritis (RA) and a useful marker in the diagnosis and classification of the disease, as well as to determine its severity and development.
Paris, France—Progress in genotyping patients with rheumatoid arthritis (RA) suggests that the amino acid valine at position 11 of the HLA-DRB1 gene appears to be the strongest independent genetic determinant of radiographic damage in this disease.
A recent review evaluating currently available data on rheumatoid arthritis (RA) diagnosis, prognosis, and prediction of response to therapy, highlights the potential of gene expression profiling in understanding RA biology, patient management, and personalized care.
A previously unknown locus for rheumatoid arthritis (RA) susceptibility has been identified by researchers from the United Kingdom involved in the genome-wide association studies (GWAS), according to a recent study.
A newly developed plasma cell (PC) 5-gene signature accurately measures PC levels in patients with scleroderma and other autoimmune diseases, including lupus and rheumatoid arthritis (RA).
By Phoebe Starr San Diego, CA—“This is an exciting time for treatment of rheumatoid arthritis [RA], with many new therapies. But the question is where do we go from here for future therapies, and what have we learned from past failures,” Arthur F. Kavanaugh, MD, Director, Center for Innovative Therapy, University of California, San Diego, La Jolla, told listeners at the 2013 American College of Rheumatology meeting.
By Wayne Kuznar San Diego, CA—Biomarkers for osteoarthritis (OA) hold great promise, but they need further refinement before they can be effectively used in clinical research and daily practice, said Erwin W.E. van Spil, MD, PhD, of the Rheumatology and Immunology Clinic, University Medical Center Utrecht, the Netherlands, at the 2013 American College of Rheumatology meeting.